IP Library Granted Patent US 7,862,555
Granted Patent B2
US 7,862,555 · App. 11/778,012 · Granted Jan 4, 2011

Apparatus and method for adjustable fractional optical dermatological treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,862,555
App. No.
11/778,012
Granted
Jan 4, 2011
Kind
B2
Abstract

In a fractional treatment system, an adjustable mechanism can be used to adjust the beam shape, beam numerical aperture, beam focus depth, and/or beam size to affect the treatment depth and or the character of the resulting lesions. Adjustment of these parameters can improve the efficiency and efficacy of treatment. Illustrative examples of adjustable mechanisms include a set of spacers of different lengths, a rotatable turret with lens elements of different focal distances, an optical zoom lens, and a mechanical adjustment apparatus for adjusting the spacing between two optical lens elements. In one aspect, the fractional treatment is configured with a laser wavelength that is selected such that absorption of the laser wavelength within the tissue decreases as the tissue is heated by the laser (e.g., 1480-1640 nm). Desirably, the laser wavelength is primarily absorbed within a treated region of skin by water and has a thermally adjusted absorption coefficient within the range of about 7 cm −1 to about 26 cm −1 .

Claims (32)

1. An apparatus for fractional dermatological treatment, the apparatus comprising:

a laser source configured to emit optical pulses having an adjustable pulse energy; and

a fractional optical treatment system configured to deliver said optical pulses to the skin, said fractional optical treatment system comprising a controller configured to automatically adjust, in response to an adjustment of the pulse energy of the optical pulse, an optical spot size at a surface of the skin in order to maximize a depth of a lesion created by the optical pulse.

2. The apparatus of claim 1 wherein said controller further, based on the pulse energy of the optical pulse, automatically adjusts a focus depth of the optical pulse in order to maximize a depth of the lesion created by the optical pulse.

3. The apparatus of claim 1 wherein said lesion extends from a surface of the skin to the dermis and wherein, when the controller increases the optical spot size at the surface of the skin, the depth of the lesion created also increases.

4. The apparatus of claim 1 wherein said controller is configured to adjust the optical spot size at the skin surface to at least one optical spot size within the range of about 100 μm to 260 μm wherein said at least one optical spot size is measured to the 1/e 2 intensity level of an optical beam providing the optical pulses.

5. The apparatus of claim 1 wherein said fractional optical treatment system includes a scanner system configured to deflect the optical pulses toward the surface of the skin.

6. The apparatus of claim 1 further comprising:

an adjustable lens group.

7. The apparatus of claim 1 further comprising:

a plurality of discretely interchangeable optical elements.

8. The apparatus of claim 1 wherein said optical source is configured to emit optical pulses having a laser wavelength that has at least one of the characteristics in the group consisting of

the thermally adjusted absorption coefficient is within the range of about 7 cm −1 to about 26 cm −1 ;

the thermally adjusted absorption coefficient is within the range of about 7 cm −1 to about 12 cm −1 ;

the absorption in water decreases by at least 12% as the temperature of water is increased from 30° C. to 80° C.;

the absorption in water decreases by about 12% to about 20% as the temperature of water is increased from 30° C. to 80° C.; and

the absorption in water decreases by about 15% to about 20% as the temperature of water is increased from 30° C. to 80° C.

9. The apparatus of claim 1 wherein said optical source is configured to emit optical pulses having a laser wavelength where:

the thermally adjusted absorption coefficient of said laser wavelength is within the range of about 7 cm −1 to about 26 cm −1 ; and

the absorption of said laser wavelength in water decreases by about 12% to about 20% as the temperature of water is increased from 30° C. to 80° C.

10. The apparatus of claim 1 wherein said optical source is configured to emit optical pulses having a laser wavelength where:

the thermally adjusted absorption coefficient for said laser wavelength is within the range of about 7 cm −1 to about 12 cm −1 ; and

the absorption of said laser wavelength in water decreases by about 15% to about 20% as the temperature of water is increased from 30° C. to 80° C.

11. The apparatus of claim 1 wherein said optical source is configured to emit optical pulses having a laser wavelength in the range of about 1480 nm to about 1640 nm.

12. The apparatus of claim 1 wherein said optical source is configured to emit optical pulses having a laser wavelength in the range of about 1560 nm to about 1640 nm.

13. The apparatus of claim 1 wherein said optical source is configured to emit optical pulses having a laser wavelength of about 1550 nm.

14. The apparatus of claim 1 wherein said optical source is configured to emit optical pulses having a laser wavelength in the range of about 1380 nm to about 1420 nm.

15. The apparatus of claim 1 wherein the fractional optical treatment system includes a contact tip configured to be in contact with the skin during the fractional dermatological treatment.

16. An apparatus for fractional dermatological treatment, the apparatus comprising:

a laser source configured to emit optical energy at a laser wavelength, wherein the absorption of said laser wavelength in water decreases as the tissue is heated from 30° C. to 80° C. and said laser wavelength is in the range of 1350 nm to 2500 nm; and

a fractional optical treatment system comprising a controller configured to adjust the optical spot size at the surface of the skin,

wherein the distance from a reference plane corresponding approximately to the contact surface of the optical system with the skin and the optical focus in air along the direction of propagation of the optical treatment beam is greater than twice the depth of the deepest portion of a lesion at a selected optical pulse energy and/or less than one half of the depth of the deepest portion of said lesion or wherein the optical focus of the optical beam is located outside the skin.

Assignments (19)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
MERGER Recorded May 14, 2021
From: RELIANT TECHNOLOGIES, LLC
To: SOLTA MEDICAL, INC.
Reel/Frame 056244/0936 →
MERGER Recorded May 12, 2021
From: RELIANT TECHNOLOGIES, INC.
To: RELIANT TECHNOLOGIES, LLC
Reel/Frame 056218/0067 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 27, 2014
From: SILICON VALLEY BANK
To: RELIANT TECHNOLOGIES, LLC
Reel/Frame 032125/0810 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: RELIANT TECHNOLOGIES, LLC
Reel/Frame 032126/0708 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Nov 19, 2013
From: RELIANT TECHNOLOGIES, LLC
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031674/0527 →
SECURITY INTEREST - MEZZANINE LOAN Recorded Apr 18, 2013
From: RELIANT TECHNOLOGIES, LLC
To: SILICON VALLEY BANK
Reel/Frame 030248/0256 →
SECURITY AGREEMENT Recorded Jun 16, 2009
From: RELIANT TECHNOLOGIES, LLC
To: SILICON VALLEY BANK
Reel/Frame 022824/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2007
From: CHAN, KIN F.; FRANGINEAS, GEORGE; DEWEY, DAVID; DEBENEDICTIS, LEONARD C.
To: RELIANT TECHNOLOGIES, INC.
Reel/Frame 019622/0261 →